Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Phase 1 Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.

Inclusion Criteria:

• Advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate
• Life expectancy of at least 3 months
• Eastern Cooperative Oncology Group performance 0-1

Exclusion Criteria:

• Any disorder with dysregulation of glucose homeostasis
• Dumping syndrome
• History of glucose intolerance